Influence of Rosiglitazone on the Expression of PPARγ, NF-κB, and TNF-α in Rat Model of Ulcerative Colitis
Figure 3
Colonic mucosal NF-κB protein expression in the control group, UC model group, and rosiglitazone treated group on days 7, 14, 21, 35. In the control group, expression of NF-κB protein in the colonic mucosa was significantly less compared to the UC model group (). In the rosiglitazone treatment group, NF-κB protein expression reduced significantly than that of the model group on days 7, 14, 21, and 35 ().
